Beyond the Label: Inconsistencies in AREDS2 Eye Supplements and a Call for Standardisation

These findings highlight a significant gap between marketed claims and clinical evidence. Most supplements do not meet the established AREDS2 standards, potentially limiting their efficacy. Some were promoted specifically for AMD, while others used general "macular health" claims, adding to patient confusion. This inconsistency underscores the need for regulatory measures to enforce standardized labeling and formulation requirements to ensure informed clinical recommendations.